Influence of Receptor Polymorphisms on the Response to α-Adrenergic Receptor Blockers in Pheochromocytoma Patients

Annika M. A. Berends 1,*, Mathieu S. Bolhuis 2, Ilja M. Nolte 3, Edward Buitenwerf 1, Thera P. Links 1, Henri J. L. M. Timmers 4, Richard A. Feelders 5, Elisabeth M. W. Eekhoff 6, Eleonora P. M. Corssmit 7, Peter H. Bisschop 8, Harm R. Haak 9,10,11,*, Ron H. N. van Schaik 12, Samira el Bouazzaoui 12, Bob Wilffert 2,13 and Michiel N. Kerstens 1

Abstract: Background: Presurgical treatment with an α-adrenergic receptor blocker is recommended to antagonize the catecholamine-induced α-adrenergic receptor mediated vasoconstriction in patients with pheochromocytoma or sympathetic paraganglioma (PPGL). There is, however, a considerable interindividual variation in the dose-response relationship regarding the magnitude of blood pressure reduction or the occurrence of side effects. We hypothesized that genetically determined differences in α-adrenergic receptor activity contribute to this variability in dose-response relationship. Methods: Thirty-one single-nucleotide polymorphisms (SNPs) of the ADRA1A, ADRA1B, ADRA1D genes were genotyped in a group of 116 participants of the PRESCRIPT study. Haplotypes were constructed after determining linkage disequilibrium blocks. Results: The ADRA1B SNP rs10515807 and the ADRA2A SNP rs553668/rs521674 were associated with higher dosages of α-adrenergic receptor blocker (p < 0.05) and with a higher occurrence of side effects (rs10515807) (p = 0.005). Similar associations were found for haplotype block 6, which is predominantly defined by rs10515807. Conclusions: This study suggests that genetic variability of α-adrenergic receptor genes might be associated with the clinically observed variation in beneficial and adverse therapeutic drug responses to α-adrenergic receptor blockers. Further studies in larger cohorts are needed to confirm our observations.
1. Introduction

Pheochromocytomas and sympathetic paragangliomas (PPGL) are rare neuroendocrine tumors localized in adrenal medulla and extra-adrenal sympathetic paraganglia, respectively [1]. The production and secretion of excessive amounts of catecholamines are cardinal features of PPGL and responsible for the associated increased cardiovascular risk [2–5]. Surgical resection of a PPGL is the only option for a cure, but it is known to be a high-risk procedure due the uncontrolled release of catecholamines [6]. In order to minimize the hyperadrenergic hemodynamic effects and prevent cardiovascular complications, pretreatment with an \( \alpha \)-adrenergic receptor blocker is usually recommended to antagonize the catecholamine-induced \( \alpha \)-adrenergic receptor mediated vasoconstriction [7].

The magnitude of blood pressure reduction or the development of side effects in response to a certain dose of an \( \alpha \)-adrenergic receptor blocker displays a considerable interindividual variability. Moreover, serious intra-operative hemodynamic instability might still occur despite presurgical treatment with high doses of an \( \alpha \)-adrenergic receptor blocker [8]. Variables explaining these interindividual differences in dose-response relationship are largely unknown at the moment.

It is conceivable that genetically determined differences in \( \alpha \)-adrenergic receptor activity contribute to the observed variation in the dose–response relationship. \( \alpha \)-Adrenergic receptors (\( \alpha \)-ARs) are G protein-coupled receptors (GPCRs) and can be classified according to their pharmacological specificity as alpha 1 (\( \alpha_1 \)-AR) or alpha 2 (\( \alpha_2 \)-AR) adrenergic receptors. Each comprises three subtypes encoded by genes on different chromosomes, denoted as \( \alpha_{1a} \)-AR (\textit{ADRA1A}; chromosome 8), \( \alpha_{1b} \)-AR (\textit{ADRA1B}; chromosome 5), \( \alpha_{1d} \)-AR (\textit{ADRA1D}; chromosome 20), \( \alpha_{2a} \)-AR (\textit{ADRA2A}; chromosome 10), \( \alpha_{2b} \)-AR (\textit{ADRA2B}; chromosome 2), and \( \alpha_{2c} \)-AR (\textit{ADRA2C}; chromosome 4). These subtypes are expressed in a wide range of tissues, including the central nervous system (predominantly \textit{ADRA1C}, \textit{ADRA2A}, \textit{ADRA2C}), blood vessels (predominantly \textit{ADRA1A}, \textit{ADRA2B}), and the heart (predominantly \textit{ADRA1C}) [9–14]. The \( \alpha \)-ARs in blood vessels play an important role in blood pressure regulation, as their activation results in vasoconstriction with increase of the peripheral vascular resistance [13,15,16]. Besides tissue-specific differences in distribution and expression levels of AR subtypes, naturally-occurring human single-nucleotide polymorphisms (SNPs) of the \( \alpha \)-ARs can also contribute to the variability in \( \alpha \)-AR-mediated physiological responses [17,18]. For instance, certain \( \alpha \)-AR genes and polymorphisms have been associated with high blood pressure and increased cardiovascular risk [19–22]. The influence of genetic variants of the \( \alpha_1 \)-AR or \( \alpha_2 \)-AR on the response to an \( \alpha \)-adrenergic receptor blocker or hemodynamic parameters, however, is largely unknown (Supplementary Table S1) [23].

We hypothesized that the response to the \( \alpha \)-adrenergic receptor blockers in patients with PPGL is modulated by certain SNPs of the \( \alpha \)-ARs gene. To this end, we evaluated in patients scheduled for PPGL resection the relationship between polymorphisms of the \( \alpha \)-AR and the degree of perioperative hemodynamic control as well as the occurrence of side effects.

2. Materials and Methods

2.1. Study Population and Design

Study subjects participated in the PRESCRIPT study, a randomized controlled trial comparing presurgical treatment with either phenoxybenzamine, a nonselective and non-competitive \( \alpha_1 \)- and \( \alpha_2 \)-adrenergic receptor blocker, or doxazosin, a selective and competitive \( \alpha_1 \)-adrenergic receptor blocker, in patients with PPGL (ClinicalTrials, number NCT01379898). The study was approved by the institutional review board of the University Medical Center Groningen, University Groningen, The Netherlands, in compliance with...
the Dutch Medical Research Involving Human Subjects Act and the Declaration of Helsinki. Written informed consent was provided by all participants. This study has been described in detail elsewhere [8]. In brief, the study population consisted of patients aged 18 years or older with non-metastatic PPGL. Past medical history of cardiovascular disease was recorded. All patients were randomized to either pretreatment with phenoxybenzamine or doxazosin. Pretreatment was started 2–3 weeks before surgery using blood pressure guided dose titration (Supplementary Table S2). Target values were blood pressure <130/80 mmHg in the supine position and a systolic blood pressure between 90–110 mmHg in the upright position. A calcium channel blocker was added when these targets were not reached despite maximum dosage of the α-adrenergic receptor blocker. A β-adrenergic receptor blocker was added in the case of heart rates >80 bpm or >100 bpm in the supine and upright position, respectively. In addition, a high-salt diet was advised and an infusion of 0.9% saline was administered within 24 h prior to surgery. Resection was postponed if the supine blood pressure was >160/100 mmHg on the day before surgery. The majority of patients were operated by minimal invasive surgical techniques (Table 1). Hemodynamic management during and after surgery was performed using a standardized operating procedure. Blood pressure and heart rate during surgery were monitored by continuous intra-arterial measurement. Intraoperative hemodynamic targets were systolic blood pressure <160 mmHg, mean arterial pressure (MAP) >60 mmHg, and heart rate <100 bpm. After surgery, patients were monitored at the post-anesthesia or intensive care unit.

Table 1. Baseline characteristics of the study population.

| Demographics               | All Subjects (n = 116) |
|----------------------------|------------------------|
| Male sex—number (%)        | 51 (44)                |
| Ethnicity                  |                        |
| European (%)               | 108 (93)               |
| Asian (%)                  | 3 (3)                  |
| African (%)                | 2 (1.5)                |
| Latin American (%)         | 2 (1.5)                |
| Arab (%)                   | 1 (1)                  |
| Age (years)                | 55 ± 15.1              |
| BMI (kg/m²)                | 25.9 ± 4.8             |
| Serum creatinine (µmol/L)  | 76.1 ± 21.7            |

| Tumor characteristics      |                          |
|----------------------------|--------------------------|
| Pheochromocytoma—number (%)| 109 (94.0)               |
| sPGL—number (%)            | 7 (6.0)                  |
| Germline mutations—number (%) | 23 (19.8)             |
| Tumor size (mm)            | 53.63 (17.50–160.00)     |
| Total plasma catecholamines (µmol/L) | 6.01 (3.53–17.26) |

| Surgical approach          |                          |
|----------------------------|--------------------------|
| Laparoscopy—number (%)     | 82 (70.7)                |
| Laparotomy—number (%)      | 20 (17.2)                |
| Posterior retropertitoneoscopic—number (%) | 14 (12.1) |

| Pretreatment               |                          |
|----------------------------|--------------------------|
| Doxazosin/Phenoxybenzamine—number (%) | 59 (51)/57 (49) |
| 8/10 mg                    | 3 (2.6)                  |
| 8/20 mg                    | 5 (4.3)                  |
| 12/40 mg                   | 5 (4.3)                  |
| 16/60 mg                   | 9 (7.8)                  |
| 20/70 mg                   | 2 (1.7)                  |
| 24/80 mg                   | 6 (5.2)                  |
| 28/90 mg                   | 1 (0.9)                  |
| 32/100 mg                  | 19 (16.4)                |
| 36/110 mg                  | 2 (1.7)                  |
| 40/120 mg                  | 14 (12.1)                |
| 48/140 mg                  | 50 (43.1)                |
| Total number of side effects | 2.0 (1.0–3.0)         |

| Pressurgical hemodynamics  |                          |
|----------------------------|--------------------------|
| Supine SBP preoperative (mmHg) * | 127.7 ± 19.1          |
| Upright SBP preoperative (mmHg) * | 118.2 ± 19.3          |
| Heart rate baseline (bpm)  | 73.0 ± 12.0             |

| Intraoperative hemodynamics|                          |
|----------------------------|--------------------------|
| Hemodynamic instability score | 43.5 (30.3–59.0)     |
| Time outside BP range (%)   | 10.0 (4.3–19.8)         |

Data are presented as number of patients (%), as mean with standard deviation, or as median with interquartile range. * With α-adrenergic receptor blockade. Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; sPGL, sympathetic paraganglioma; bpm, beats per minute; BMI, body mass index.
2.2. Data Recording and Analysis

All data on blood pressure, heart rate, and medication was extracted from the electronic patient data monitoring system starting at first visit and ending at discharge from the post-anesthesia care unit or intensive care unit. Treatment follow-up was performed using a strict and standardized pretreatment protocol. During the whole pretreatment period, blood pressure and heart rate were measured twice daily with a certified automated electronic blood pressure monitor just before ingestion of the study drugs. Each measurement consisted of a single recording after 5 min of supine rest and subsequently after 3 min in upright posture. Side-effects of α-adrenergic receptor blockers were self-recorded by using a structured patient diary. Furthermore, both duration and amplitude of hemodynamic variables outside the target range were assessed, and cumulative dosage of vasoactive medication was calculated. The degree of intraoperative hemodynamic instability was assessed by using the hemodynamic instability score [24], which consists of three components: hemodynamic variables (i.e., blood pressure and heart rate), cumulative dosage of vasoactive medication, and volume therapy. A higher hemodynamic instability score represents a higher degree of overall hemodynamic instability.

2.3. DNA Collection and Genetic Analyses

DNA was extracted and samples were diluted with a Tris-EDTA (TE) buffer to a volume of 50 µL with a minimum concentration of 10 ng/µL. Samples were stored in a half-deep well plate (Thermo Scientific, Waltham, MA, USA, 0.8 mL 96 well storage plate, art.nr. AB-0765) protected with a removable heat seal and kept at −80 °C until analysis.

All DNA samples were analyzed at the Department of Clinical Chemistry at the Erasmus Medical Center (Rotterdam, the Netherlands). All known single nucleotide polymorphisms (SNPs) of α-AR 1A (ADRA1A), 1B (ADRA1B), 1D (ADRA1D), 2A (ADRA2A), 2B (ADRA2B), and 2C (ADRA2C) were selected for analysis, resulting in a final list of 31 SNPs (Supplementary Table S1). For rs1048101, rs1383914, rs13278849 (ADRA1A), rs1800544, and rs1800545 (ADRA2A), genotyping was performed on the Life Technologies Taqman® 7500 system (Applied Biosystems, Life Technologies Europe BV, Bleiswijk, The Netherlands). For the other 26 SNPs (see Supplementary Table S1), the Quantstudio 12K Flex (Thermo Fisher) was used. With this method, two probes, one for the wildtype and one for the variant sequence, are coupled with FAM or VIC reporter dyes, of which the fluorescent signal is measured at, respectively, 530 nm and 554 nm to distinguish between wild-type, heterozygote, or homozygote. Genotyping was carried out according to the manufacturer’s instructions.

2.4. Statistical Analyses

Continuous variables are described by their mean and standard deviation, when they are normally distributed, or by median and interquartile range, if their distributions were skewed. For categorical variables, counts and frequencies are presented.

Firstly, the four outcome variables—dose of α-adrenergic receptor blockers, total number of side effects, hemodynamic instability score, and the cumulative time outside the blood pressure target range during surgery—were analyzed univariably with the potential confounders age, sex, body mass index, systolic blood pressure at baseline in supine position, total number of antihypertensive comediations at baseline, tumor size, plasma levels of catecholamines, serum creatinine, and randomization arm of the trial (i.e., treatment with either doxazosin or phenoxybenzamine). The latter two outcomes were analyzed using linear regression, for which the cumulative time outside the blood pressure target range during surgery was square root transformed to render a normal distribution. The outcomes dose of α-adrenergic receptor blockers and total number of side effects were categorical variables, and therefore ordinal regression was used for their association analysis. The various incremental dosages of each α-adrenergic receptor blocker were arbitrarily transformed into three incremental dosage steps (i.e., low, consisting of doxazosin 0–8 mg or phenoxybenzamine 0–20 mg; moderate, consisting of doxasozin
12–28 mg or phenoxybenzamine 40–90 mg; and high, consisting of doxazosin 32–48 mg or phenoxybenzamine 100–140 mg) to meet with the assumption of proportional odds (Supplementary Table S2). Total number of side effects were categorized in 0, 1, 2, 3, or ≥4 side effects. Covariables with a $p$-value below 0.2 were considered as confounders and included in subsequent analyses.

Secondly, the SNPs were associated with the outcomes using an additive model, which is that the effect of the homozygotes was modeled as being double the effect of heterozygotes, while adjusting for confounders. SNPs were excluded from the analyses if the quality of the SNP was regarded insufficient, based on the following criteria: a call rate (i.e., number of samples with a non-missing genotype) <80%, a minor allele frequency < 5%, or a deviation of the Hardy-Weinberg equilibrium ($p$-value < 0.05/31). The call rate per sample was calculated to determine the quality of the samples. For the SNP analyses, none of the samples was excluded.

In addition, haplotype analyses were performed. Haplotype blocks were constructed using the confidence intervals method in Haploview [25,26]. Within each block, haplotypes were constructed using the haplo.em() function from the haplo.stats package [27]. Only samples with a call rate ≥0.5 were included in this analysis ($n = 110$). The most likely haplotype combination was assigned to each individual, provided that the haplotype probability was >0.7. Otherwise, it was set to missing. Next, for each haplotype that occurred at least 10 times in the dataset, an association analysis was carried out using an additive model adjusting for covariables.

Two sensitivity analyses were performed: one using only the samples with a call rate >50% and one using only the European samples, to test if the quality of the samples or the ethnicity of the samples influenced the results.

Because we tested 24 SNPs, a multiple testing correction for statistical significance was required. Because SNPs were not all independent, linkage disequilibrium was calculated. SNPs in at least moderate linkage disequilibrium ($r^2 > 0.5$) were considered to be dependent. This yielded 14 independent tests, so the $p$-value threshold for statistical significance was 0.05/14 = 0.0036. All analyses were performed using R version 3.6 [28].

3. Results

Of the 134 patients who had participated in the PRESCRIPT trial, samples of 16 patients were not retrievable from the biobank. In addition, samples of two patients contained too little DNA for genotyping. Thus, SNP analysis was performed in 116 patients with either a pheochromocytoma (94%) or a sympathetic paraganglioma (6%). Baseline characteristics are shown in Table 1. Mean age of the study population was $55 \pm 15.1$ years, and the majority (93%) were of European ancestry. Side-effects of $\alpha$-adrenergic receptor blockers were recorded as dizziness ($n = 64$), dry mouth ($n = 12$), dry eyes ($n = 3$), nasal congestion ($n = 30$), fatigue ($n = 30$), headache ($n = 20$), palpitations ($n = 16$), abdominal distension ($n = 23$), obstipation ($n = 5$), dyspnea ($n = 7$), urinary incontinence ($n = 4$), or peripheral edema ($n = 8$).

Age, female sex, body mass index, systolic blood pressure at baseline in supine position, and total number of antihypertensive comediations were all nominally significantly associated with the dose of $\alpha$-adrenergic receptor blockers (Table 2). No significant effect on the dose was observed for tumor size, plasma levels of total catecholamines, serum creatinine, or randomization arm. Only body mass index was significantly associated with the number of side effects in the multivariable model. The randomization arm of the trial was significantly associated with the hemodynamic instability score in the multivariable model, while body mass index, baseline systolic blood pressure in supine position, and plasma levels of total catecholamines showed a suggestive association. Total plasma levels of catecholamines were the only variable demonstrating a significant association with the cumulative intraoperative time outside the blood pressure target range.
Table 2. Associations of covariates with dose of α-adrenergic receptor blockers, number of side effects, hemodynamic instability score, and cumulative intraoperative time outside the blood pressure target range.

| Outcome                                      | Covariate                        | Beta  | SE     | Univariate p-Value | Multivariate p-Value |
|----------------------------------------------|----------------------------------|-------|--------|--------------------|----------------------|
| Dose of α-adrenergic receptor blockers       | Age                              | 0.046 | 0.013  | 0.00092            | 0.094                |
|                                              | Sex (female)                     | −0.77 | 0.38   | 0.044              | 0.025                |
|                                              | BMI                              | 0.19  | 0.053  | 0.00059            | 0.011                |
|                                              | SBP baseline (supine)            | 0.047 | 0.0106 | 0.00029            | 0.0013               |
|                                              | Number of antihypertensive        | 0.92  | 0.28   | 0.0014             | 0.069                |
| complementary day -1 (baseline)             | Serum creatinine                 | 0.0057| 0.0086 | 0.50               | n.a.                 |
|                                              | Tumor size                       | −0.00024| 0.0006 | 0.70               | n.a.                 |
|                                              | Catecholamines                   | 0.0087| 0.0109 | 0.43               | n.a.                 |
|                                              | Randomization                    | −0.089| 0.36   | 0.80               | n.a.                 |
|                                              |                                   |       |        |                    |                      |
| Number of side effects                       | Age                              | −0.003| 0.011  | 0.78               | n.a.                 |
|                                              | Sex (female)                     | 0.33  | 0.33   | 0.32               | n.a.                 |
|                                              | BMI                              | −0.066| 0.034  | 0.06               | 0.045                |
|                                              | SBP baseline (supine)            | 0.004 | 0.007  | 0.55               | n.a.                 |
|                                              | Number of antihypertensive        | 0.39  | 0.22   | 0.07               | 0.16                 |
| complementary day -1 (baseline)             | Serum creatinine                 | −0.003| 0.008  | 0.74               | n.a.                 |
|                                              | Tumor size                       | −0.0003| 0.0006 | 0.61               | n.a.                 |
|                                              | Catecholamines                   | 0.012 | 0.009  | 0.17               | 0.38                 |
|                                              | Randomization                    | −0.43 | 0.33   | 0.20               | 0.29                 |
|                                              | Dose of α-adrenergic             | 0.15  | 0.24   | 0.53               | n.a.                 |
| receptor blockers                            |                                   |       |        |                    |                      |
|                                              |                                   |       |        |                    |                      |
| Hemodynamic instability score                | Age                              | 0.23  | 0.14   | 0.11               | 0.22                 |
|                                              | Sex (female)                     | −1.39 | 4.32   | 0.75               | n.a.                 |
|                                              | BMI                              | −0.69 | 0.45   | 0.13               | 0.15                 |
|                                              | SBP baseline (supine)            | 0.21  | 0.09   | 0.018              | 0.11                 |
|                                              | Number of antihypertensive        | 1.76  | 2.70   | 0.52               | n.a.                 |
| complementary day -1 (baseline)             | Serum creatinine                 | −0.10 | 0.10   | 0.30               | n.a.                 |
|                                              | Tumor size                       | 0.011 | 0.007  | 0.11               | 0.40                 |
|                                              | Catecholamines                   | 0.36  | 0.12   | 0.0032             | 0.15                 |
|                                              | Randomization                    | 9.63  | 4.20   | 0.024              | 0.026                |
|                                              |                                   |       |        |                    |                      |
| Cumulative intraoperative                    | Age                              | −0.013| 0.62   | 0.25               | n.a.                 |
| time outside the blood pressure              | Sex (female)                     | −0.28 | 0.33   | 0.40               | n.a.                 |
| target range                                 | BMI                              | −0.038| 0.035  | 0.28               | n.a.                 |
|                                              | SBP baseline (supine)            | 0.003 | 0.007  | 0.67               | n.a.                 |
|                                              | Number of antihypertensive        | 0.23  | 0.21   | 0.28               | n.a.                 |
| complementary day -1 (baseline)             | Serum creatinine                 | −0.0027| 0.0076| 0.73               | n.a.                 |
|                                              | Tumor size                       | 0.00054| 0.00056| 0.34               | n.a.                 |
|                                              | Catecholamines                   | 0.02  | 0.0093 | 0.031              | 0.031                |
|                                              | Randomization                    | 0.063 | 4.12   | 0.33               | n.a.                 |

SE, standard error; n.a., not applicable.

Quality control of the SNP genotyping showed that three SNPs had an insufficient call rate. For four SNPs, the minor allele frequency was below 5%. All SNPs were in Hardy–Weinberg equilibrium, resulting in 24 SNPs left for analysis. The SNP association analyses adjusted for confounders revealed three SNPs that were nominally significantly associated with dose of α-adrenergic receptor blockers (rs10515807 (p = 0.047), rs521674 (p = 0.014), and rs553668 (p = 0.024)) (Table 3). The G alleles of rs10515807 in the ADRA1B gene and rs553668 in the ADRA2A gene both caused a three times lower risk of being in a higher dosage step than allele A (odds ratio (OR) = 0.31 and 0.26, respectively), while the T allele of rs521674 in ADRA2A was associated with a three times higher risk than the A allele (OR = 3.30). The associations remained unchanged when low quality samples were excluded but became less significant when only European samples were analyzed (Supplementary Table S3). SNP rs10515807 was also nominally associated with the number of side effects in the multivariable model (p = 0.005), and this association did not change when low-quality or non-European samples were removed (Table 3; Supplementary Table S4). However,
none of these significances survived the multiple testing correction. No SNP associations were observed for the hemodynamic instability score or the cumulative intraoperative time outside the blood pressure target range in the cohort as a whole (Table 3).

| Gene Block | SNP-Allele | OR (SE) | p-Value | OR (SE) | p-Value | Beta (SE) | p-Value | Beta (SE) | p-Value |
|------------|------------|---------|---------|---------|---------|-----------|---------|-----------|---------|
| ADRA1A     | rs229169-T  | 0.73 (0.37) | 0.39     | 0.98 (0.27) | 0.95     | 0.36 (0.31) | 0.91     | -0.04 (0.26) | 0.87     |
| ADRA1A     | rs2030373-C | 0.52 (0.46) | 0.17     | 0.58 (0.37) | 0.14     | 0.58 (0.417) | 0.89     | 0.02 (0.33) | 0.96     |
| ADRA1A     | rs6884105-G | 0.67 (0.40) | 0.31     | 0.95 (0.28) | 0.85     | 0.49 (0.32) | 0.88     | 0.06 (0.26) | 0.82     |
| ADRA1A     | rs756275-T  | 0.70 (0.67) | 0.59     | 1.01 (0.54) | 0.98     | 3.18 (5.97) | 0.60     | -0.13 (0.46) | 0.78     |
| ADRA1A     | rs6892282-T | 1.35 (0.35) | 0.39     | 1.58 (0.27) | 0.10     | -3.53 (2.39) | 0.30     | -0.50 (0.25) | 0.05     |
| ADRA1A     | rs10515807-G | 0.31 (0.58) | 0.047*   | 0.27 (0.46) | 0.005*   | -2.18 (5.09) | 0.67     | 0.26 (0.38) | 0.50     |
| ADRA1A     | rs6888306-T | 0.89 (0.38) | 0.77     | 1.23 (0.32) | 0.52     | -4.67 (3.77) | 0.22     | -0.28 (0.28) | 0.32     |
| ADRA1A     | rs13162302-G | 1.00 (0.40) | 0.94     | 1.27 (0.33) | 0.47     | -6.79 (4.02) | 0.10     | -0.43 (0.30) | 0.15     |
| ADRA1A     | rs11750092-T | 1.20 (0.40) | 0.66     | 1.36 (0.33) | 0.36     | -7.56 (4.02) | 0.06     | -0.46 (0.30) | 0.15     |
| ADRA1A     | rs1800544-G | 2.01 (0.38) | 0.12     | 1.16 (0.32) | 0.64     | -1.72 (4.00) | 0.67     | 0.18 (0.30) | 0.56     |
| ADRA1A     | rs17426222-T | 2.01 (0.45) | 0.12     | 1.16 (0.32) | 0.64     | -1.72 (4.00) | 0.67     | 0.18 (0.30) | 0.56     |
| ADRA1A     | rs4732957-C | 1.35 (0.35) | 0.39     | 1.58 (0.27) | 0.10     | -3.53 (2.39) | 0.30     | -0.50 (0.25) | 0.05     |
| ADRA1A     | rs735114-G | 1.19 (0.37) | 0.09     | 1.04 (0.28) | 0.90     | -2.77 (3.30) | 0.40     | 0.16 (0.25) | 0.52     |
| ADRA1A     | rs1383914-T | 1.41 (0.32) | 0.29     | 1.21 (0.24) | 0.43     | -2.64 (3.00) | 0.38     | -0.02 (0.23) | 0.95     |
| ADRA1A     | rs3608585-T | 0.74 (0.40) | 0.46     | 1.31 (0.29) | 0.36     | 2.34 (3.59) | 0.52     | -0.04 (0.29) | 0.89     |
| ADRA1A     | rs521674-T | 1.30 (0.48) | 0.014*   | 1.04 (0.32) | 0.91     | 1.41 (4.04) | 0.73     | -0.08 (0.31) | 0.81     |
| ADRA1A     | rs1805544-G | 2.01 (0.38) | 0.07     | 1.23 (0.29) | 0.48     | -0.11 (3.57) | 0.98     | -0.02 (0.28) | 0.95     |
| ADRA1A     | rs180354-A  | 1.03 (0.36) | 0.60     | 0.97 (0.43) | 0.75     | 4.92 (4.33) | 0.37     | 0.40 (0.41) | 0.34     |
| ADRA1A     | rs533668-G  | 0.26 (0.59) | 0.024*   | 0.72 (0.38) | 0.39     | 1.12 (4.69) | 0.81     | 0.27 (0.35) | 0.44     |
| ADRA1A     | rs2236554-T | 0.85 (0.40) | 0.69     | 1.11 (0.31) | 0.73     | -5.24 (4.06) | 0.20     | -0.34 (0.30) | 0.27     |
| ADRA1A     | rs1556832-T | 0.63 (0.36) | 0.20     | 0.87 (0.25) | 0.58     | -4.75 (3.15) | 0.14     | -0.18 (0.24) | 0.46     |

AF, allele frequency; OR, odds ratio; SE, standard error, * nominal significant.

Linkage disequilibrium analyses showed that, within the ADRA1A gene, three haplotype blocks could be determined: one block within the ADRA2A gene and two blocks within the ADRA1B gene (Figure 1). The haplotype analyses revealed nominally significant associations of haplotype A-C-A-C in block 6, consisting of SNPs rs10515807, rs6888306, rs13162302, and rs11750092 in the ADRA1B gene with both a higher dose of α-adrenergic receptor blockers (OR = 3.30; p = 0.044) and a higher number of side effects (OR = 3.51; p = 0.007) (Table 4). Another haplotype in the same block (G-C-A-C), that differs only in the first position (i.e., rs10515807), was associated with a lower number of side effects (OR = 0.55; p = 0.049) (Table 4). These associations did, however, not survive multiple testing correction. No haplotype associations were observed with the hemodynamic instability score and the cumulative intraoperative time outside the blood pressure target range (Table 4).

Table 3. Association of the SNPs with dose of α-adrenergic receptor blockers, number of side effects, the hemodynamic instability score, and the cumulative intraoperative time outside the blood pressure target range.

Table 4. Haplotype analyses.
Table 4. Cont.

| Gene | Block # | Haplotype | OR (SE) | p-Value | OR (SE) | p-Value | Beta (SE) | p-Value | Beta (SE) | p-Value |
|------|---------|-----------|---------|----------|---------|----------|-----------|----------|-----------|----------|
| ADRA1A | 3 | C-A-T-C | 0.72 (0.58) | 0.57 | 1.42 (0.51) | 0.49 | 3.68 (5.64) | 0.52 | −0.54 (0.44) | 0.22 |
| ADRA1A | 3 | C-G-T-C | 1.74 (0.36) | 0.13 | 1.06 (0.28) | 0.84 | −2.46 (3.28) | 0.46 | 0.18 (0.25) | 0.48 |
| ADRA1B | 3 | T-A-C-C | 0.78 (0.37) | 0.51 | 0.62 (0.31) | 0.13 | −1.95 (3.90) | 0.62 | −0.01 (0.29) | 0.97 |
| ADRA1B | 3 | T-A-C-T | 0.87 (0.41) | 0.74 | 1.18 (0.30) | 0.58 | 2.81 (3.63) | 0.44 | 0.00 (0.29) | 0.99 |
| ADRA1B | 5 | A-A-C-T | 1.93 (0.46) | 0.16 | 1.86 (0.37) | 0.10 | −1.45 (4.12) | 0.73 | −0.08 (0.33) | 0.80 |
| ADRA1B | 5 | C-A-T-T | 1.58 (0.86) | 0.60 | 0.58 (0.55) | 0.33 | 6.49 (6.50) | 0.32 | −0.19 (0.49) | 0.70 |
| ADRA1B | 5 | C-G-C-G | 0.71 (0.36) | 0.34 | 0.66 (0.28) | 0.15 | 3.65 (3.29) | 0.27 | 0.35 (0.26) | 0.19 |
| ADRA1B | 5 | C-G-C-T | 1.71 (0.71) | 0.45 | 1.85 (0.50) | 0.22 | −5.56 (6.22) | 0.37 | −0.69 (0.16) | 0.44 |
| ADRA1B | 6 | A-C-A-C | 3.30 (0.58) | 0.044* | 3.51 (0.46) | 0.007* | 2.54 (5.06) | 0.62 | −0.30 (0.38) | 0.43 |
| ADRA1B | 6 | G-C-A-C | 0.72 (0.38) | 0.88 | 0.55 (0.30) | 0.05 | 3.04 (3.76) | 0.42 | 0.38 (0.28) | 0.18 |
| ADRA1B | 6 | G-T-A-T | 0.49 (0.85) | 0.40 | 0.83 (0.67) | 0.78 | 4.66 (7.84) | 0.33 | 0.42 (0.56) | 0.46 |
| ADRA1B | 6 | G-T-G-T | 1.02 (0.42) | 0.96 | 1.16 (0.34) | 0.67 | −7.82 (4.17) | 0.07 | −0.38 (0.31) | 0.23 |
| ADRA2A | 4 | A-C-G-G | 0.47 (0.39) | 0.056 | 0.94 (0.30) | 0.83 | −0.36 (3.65) | 0.92 | 0.11 (0.28) | 0.69 |
| ADRA2A | 4 | T-G-G-A | 2.71 (0.51) | 0.055 | 1.33 (0.37) | 0.44 | −3.60 (4.53) | 0.43 | −0.34 (0.35) | 0.33 |
| ADRA2A | 4 | T-G-A-G | 1.55 (0.37) | 0.44 | 0.81 (0.44) | 0.62 | 5.79 (5.46) | 0.29 | 0.19 (0.41) | 0.65 |

* Block 1, rs3802241-rs1048101; block 2, rs13278849-rs17426222-rs4732957; block 3, rs4732682-rs573514-rs1383914-rs3808585; block 4, rs521674-rs1800544-rs1800545-rs553668; block 5, rs2030373-rs6884105-rs756275-rs6892282; block 6, rs10515807-rs6888306-rs13162302-rs11750092. OR, odds ratio; SE, Standard error; * nominal-significant (p < 0.05).

Figure 1. Haplotype blocks within the candidate genes. Linkage disequilibrium plot of the SNPs that were genotyped in ADRA2D (SNPs 1–2), ADRA1A (SNPs 3–14), ADRA2B (SNP 15), ADRA2A (SNPs 19–23), and ADRA1B (SNPs 24–31). The color scheme is a reflection of $D'$ (white meaning no linkage disequilibrium ($D' = 0$) and red complete linkage disequilibrium ($D' = 1$)). Haplotype blocks have been calculated using the confidence intervals method (Gabriel 2002). Numbers inside the squares refer to values of $D'$, with no number indicating complete linkage disequilibrium. SNP = single nucleotide polymorphism.

4. Discussion

In this study, we investigated, in a well-defined group of patients undergoing resection of a PPGL, whether polymorphisms of the $\alpha$-AR genes affect the clinical response to presurgical administration of $\alpha$-adrenergic receptor blockers. Our findings showed that patients carrying minor alleles for a SNP in the intron region (rs10515807-A) of the ADRA1B gene or for SNPs in the three prime untranslated region (rs553668-A) or the 2kb upstream...
region (rs521674-T) of the ADRA2A gene needed a higher dosage of an α-adrenergic receptor blocker. In addition, it was found that patients with the A allele of the rs10515807 SNP seemed to be more prone to developing α-adrenergic receptor blocker-related side-effects, independently of the prescribed dosage. Haplotype analysis produced additional evidence for this relationship, with predominantly a role for the ADRA1B gene. However, none of these associations remained significant after correction for multiple testing.

AR genes are highly polymorphic and demonstrate genetic variations in both coding and non-coding regions. Adrenoreceptors are the target for several frequently prescribed drugs, especially in cardiovascular medicine, and represent pharmacodynamic candidate genes [12]. To date, only a few small-sized studies have addressed the potential clinical consequences of polymorphisms of the genes encoding adrenergic receptors [29]. Most available studies were focused on beta adrenergic receptors (β-ARs) and to a lesser extent on α₂-AR (ADRA2A, ADRA2B, ADRA2C) (Supplementary Table S1) [14,16,17,30].

The human ADRA1B gene consists of two exons separated by a single large intron of 20 kb that interrupts the coding region at the end of the putative sixth transmembrane domain [31]. Thus far, data on the potential relationship between polymorphisms of the ADRA1B gene and the efficacy of α-adrenergic receptor blockers are very limited. It has been shown that prazosin, an α1-adrenergic receptor blocker, binds with equal affinity to both ADRA1B and ADRA1A, the latter being the principal mediator of vasoconstriction [13,32]. In a study among normotensive and hypertensive subjects, no relationship was found between four exonic ADRA1B polymorphisms and the blood pressure response to intravenous administration of the ADRA1B agonist phenylephrine [31]. In contrast, an intronic variant (rs10070745) of ADRA1B present in African Americans was associated with an enhanced vasoconstrictor response to phenylephrine [33]. The present study is the first to suggest a decreased efficacy of α-adrenergic receptor blockers as well as an increased susceptibility to adverse effects to these antihypertensive agents in carriers of the intronic G > A variant in rs10515807. It could be postulated that this polymorphism results in a decreased affinity of the ADRA1B, which would explain the need of a higher drug dose. Such a change in receptor affinity, however, would not provide an explanation for the observed association between this polymorphism and the enhanced susceptibility to adverse effects, which was also independent of the dose. Possible explanations could include, e.g., modulation of crosstalk between certain SNPs or cosegregation with other SNPs affecting pathways involved in the development of adverse effects, but these suggestions remain quite speculative. Additional studies are needed to further elucidate the functional consequences of these SNPs.

The human ADRA2A gene is intronless and consists of one single 3650-base pair (bp) exon, which contains a 1353-bp open reading frame encoding a receptor protein of 450 amino acid residues [34]. Activation of the presynaptic ADRA2A results in a decrease of blood pressure and heart rate through negative feedback inhibition of the catecholamine secretion. ADRA2A knock-out mice were found to demonstrate a hyperadrenergic phenotype with elevated blood pressure and diminished hypotensive response to administration of clonidine [35]. We found that two ADRA2A SNPs, i.e., rs553668, formerly described as the DraI restriction fragment length polymorphism (RFLP), and rs521674, were associated with a higher requirement of α-adrenergic receptor blockers, suggesting that these polymorphisms result in a decreased inhibition of the presynaptic catecholamine release. This is more or less in agreement with a previous study demonstrating that carriers of the variant allele of rs553668 experienced a less pronounced blood pressure drop during exercise [36]. Of interest, in vitro experiments with human neuronal cells demonstrated that transfection with the rs553668 variant was associated with a decreased protein expression in subjects from European ancestry [37]. Thus, the higher requirement of α-adrenergic receptor blockers in patients with pheochromocytoma harboring the rs553668 polymorphisms of the ADRA2A gene could be due to a lower presynaptic receptor density. The relationship between blood pressure or antihypertensive drug response and the rs521674
polymorphism of the \textit{ADRA2A} gene has not been described before and requires further investigations for determining the possible underlying mechanism.

We were unable to find an association between \(\alpha\)-AR variants and the hemodynamic profile during surgical resection of the PPGL. This might be explained by the fact that the primary endpoint of the PRESCRIPT study, defined as the cumulative intraoperative time of blood pressure outside the target range, also did not reach significance \cite{8}. Intraoperative blood pressure during PPGL resection is affected by many different factors, including general health status, catecholamine secretion, and vaso-active drugs administration. Consequently, to identify the influence of a genetic polymorphism amidst these complex and interacting factors would require a substantial effect size of such a variant in order to be demonstrated.

Our study had several strengths and limitations. A major strength of the current study is that we used a comprehensive prospective data collection derived from the only randomized controlled trial examining the efficacy of \(\alpha\)-adrenergic receptor blockers in a large group of patients with a PPGL. In addition, this is the first study evaluating the relationship between the therapeutic response of \(\alpha\)-adrenergic receptor blockers in patients who underwent a PPGL resection. Moreover, we used haplotype analysis, which can identify susceptibility loci that are not captured by single genetic variation test alone \cite{25,38}.

There are, however, also limitations that need to be addressed. As indicated earlier, we found nominally significant associations for three variants, but none of these associations remained significant after correction for multiple testing. This could be due to a lack of statistical power, despite the fact that the study population is one of the largest of its kind. As a result, our findings should be mainly considered as hypothesis generating and require validation in larger clinical cohorts. We did not investigate SNPs of the \textit{ADRA2C} gene, but most study participants were white subjects, and polymorphisms of this gene are infrequent in a white population \cite{12,29}. Moreover, we focused on SNPs concerning genes of the receptor itself, assuming these are the major contributors. One disadvantage of such an approach is that the complex system of the biology of drug actions in vivo probably may not be fully addressed. Additionally, there could be physiological relevant signaling pathways for this \(\alpha\)-AR subtypes that have not been elucidated yet, and polymorphisms in genes contributing to the signal transduction of these GPCRs could also be of interest.

In conclusion, this study indicates that genetic variants in \textit{ADRA1B} and \textit{ADRA2A} could modify \(\alpha\)-adrenergic receptor blocker efficacy and the risk of developing side effects in PPGL patients pretreated with \(\alpha\)-adrenergic receptor blockers. Future studies in larger cohorts are required to confirm our observations, which could open the way to personalized medicine based on pharmacogenetics in the management of patients with a PPGL.

Supplementary Materials: The following are available online at https://www.mdpi.com/10.3390/biomedicines10040896/s1, Table S1: Overview of the single nucleotide polymorphisms of the alpha 1 and alpha 2 adrenergic receptor evaluated in the present study and the associated clinical conditions that have been reported in the literature, Table S2: Standardized incremental dosage steps for doxazosin and phenoxybenzamine, Table S3: Sensitivity analyses for dose of alpha adrenergic receptor blockers, Table S4: Sensitivity analyses for number of side effects. References \cite{17,22,23,25,30,39–89} are cited in the Supplementary Materials.

Author Contributions: Conceptualization, A.M.A.B., M.S.B., I.M.N., B.W. and M.N.K.; methodology, A.M.A.B., M.S.B., I.M.N., S.e.B., R.H.N.v.S., B.W. and M.N.K.; formal analysis, A.M.A.B., M.S.B., I.M.N., S.e.B., R.H.N.v.S., B.W. and M.N.K.; data curation, A.M.A.B., M.S.B. and M.N.K.; writing—original draft preparation, A.M.A.B., M.S.B., I.M.N. and M.N.K.; writing—review and editing, A.M.A.B., M.S.B., I.M.N., E.B., T.P.L., H.J.L.M.T., R.A.F., E.M.W.E., E.P.M.C., P.H.B., H.R.H., R.H.N.v.S., S.e.B., B.W., M.N.K.; visualization, A.M.A.B. and I.M.N.; supervision, M.N.K.; project administration, A.M.A.B. and M.N.K.; funding acquisition, not applicable. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.
Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of the University Medical Center Groningen (ClinicalTrials.gov number NCT01379898, protocol code 2010-369 and date of approval: 18 April 2011).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: All data generated or analyzed during this study are included in this published article (and its Supplementary Materials).

Acknowledgments: Several authors of this publication are members of the European Reference Network on rare endocrine conditions—Project ID No 739527.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Loyd, R.V.; Osamura, R.Y.; Kloppel, G.; Rosai, J. WHO Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organ, 4th ed; IARC: Lyon, France, 2017.
2. Stolk, R.F.; Bakx, C.; Mulder, J.; Timmers, H.J.; Lenders, J.W. Is the excess cardiovascular morbidity in pheochromocytoma related to blood pressure or to catecholamines? J. Clin. Endocrinol. Metab. 2013, 98, 1100–1106. [CrossRef] [PubMed]
3. Giavarini, A.; Chedid, A.; Bobrie, G.; Plouin, P.F.; Hagege, A.; Amar, L. Acute catecholamine cardiomyopathy in patients with pheochromocytoma or functional paraganglioma. Heart 2013, 99, 1438–1444. [CrossRef]
4. Reister, A.; Weismann, D.; Quinkler, M.; Lichtenauer, U.D.; Sommerey, S.; Halbritter, R.; Penning, R.; Spitzweg, C.; Schopohl, J.; Beuschlein, F.; et al. Life-threatening events in patients with pheochromocytoma. Eur. J. Endocrinol. 2015, 173, 757–764. [CrossRef] [PubMed]
5. Gu, Y.W.; Poste, J.; Kunal, M.; Schwarz, M.; Weiss, I. Cardiovascular manifestations of pheochromocytoma. Cardiol. Rev. 2017, 25, 215–222. [CrossRef] [PubMed]
6. Berends, A.M.A.; Kerstens, M.N.; Lenders, J.W.M.; Timmers, H.J.L.M. Approach to the Patient: Perioperative Management of the Patient with Pheochromocytoma or Sympathetic Paraganglioma. J. Clin. Endocrinol. Metab. 2020, 105, dgaa441. [CrossRef] [PubMed]
7. Lenders, J.W.M.; Duh, Q.Y.; Eisenhofer, G.; Gimenez-Roqueplo, A.P.; Grebe, S.K.; Murad, M.H.; Naruse, M.; Pacak, K.; Young, W.F.; Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2014, 99, 1915–1942. [CrossRef]
8. Buitenwerf, E.; Oisinga, T.E.; Timmers, H.J.L.M.; Lenders, J.W.M.; Feelders, R.A.; Eekhoff, E.M.W.; Haak, H.R.; Corssmit, E.P.M.; Bisschop, P.H.L.T.; Valk, G.D.; et al. Efficacy of α-blockers on hemodynamic control during pheochromocytoma resection: A randomized controlled trial. J. Clin. Endocrinol. Metab. 2020, 105, 2381–2391. [CrossRef]
9. Price, D.T.; Lefkowitz, R.J.; Caron, M.G.; Berkowitz, D.; Schwinn, D.A. Localization of mRNA for three distinct alpha 1-adrenergic receptor subtypes in human tissues: Implications for human alpha-adrenergic physiology. Mol. Pharmacol. 1994, 45, 171–175. [CrossRef]
10. Rudner, X.L.; Berkowitz, D.E.; Booth, J.V.; Funk, B.L.; Cozart, K.L.; D’Amico, E.B.; El-Moalem, H.; Page, S.O.; Richardson, C.D.; Winters, B.; et al. Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation 1999, 100, 2336–2343. [CrossRef]
11. Guimarães, S.; Moura, D. Vascular adrenoceptors: An update. Pharmacol. Rev. 2001, 53, 319–356.
12. Flordellis, C.; Paris, H.; Karabinis, A.; Lymperopoulos, A. Pharmacogenomics of adrenoceptors. Pharmacogenomics 2004, 5, 803–817. [CrossRef] [PubMed]
13. Docherty, J.R. Subtypes of functional alpha1-adrenoceptor. Cell Mol. Life Sci. 2010, 67, 405–417. [CrossRef] [PubMed]
14. Giovannitti, J.A., Jr.; Thoms, S.M.; Crawford, J.J. Alpha-2 adrenergic receptor agonists: A review of current clinical applications. Anesth. Prog. 2015, 62, 31–39. [CrossRef]
15. Docherty, J.R. Subtypes of functional alpha1- and alpha2-adrenoceptors. Eur. J. Pharmacol. 1998, 361, 1–15. [CrossRef]
16. Flordellis, C.; Manolis, A.; Scheinin, M.; Paris, H. Clinical and pharmacological significance of alpha2-adrenoceptor polymorphisms in cardiovascular diseases. Int. J. Cardiol. 2004, 97, 367–372. [CrossRef] [PubMed]
17. Small, K.M.; Liggett, S.B. Identification and functional characterization of alpha(2)-adrenergic receptor polymorphisms. Trends Pharmacol. Sci. 2001, 22, 471–477. [CrossRef]
18. Shastry, B.S. SNPs: Impact on gene function and phenotype. Methods Mol. Biol. 2009, 578, 3–22.
19. Lockette, W.; Ghosh, S.; Farrow, S.; Mackenzie, S.; Baker, S.; Miles, P.; Schork, A.; Cadaret, L. Alpha 2-adrenergic receptor gene polymorphism and hypertension in blacks. Am. J. Hypertens. 1995, 8, 390–394. [CrossRef]
20. Svetkey, L.P.; Timmons, P.Z.; Emovon, O.; Anderson, N.B.; Preis, L.; Chen, Y.T. Association of hypertension with beta2- and alpha2c10-adrenergic receptor genotype. Hypertension 1996, 27, 1210–1215. [CrossRef]
21. Freitas, S.R.; Pereira, A.C.; Floriano, M.S.; Mill, J.G.; Krieger, J.E. Association of alpha1a-adrenergic receptor polymorphism and blood pressure phenotypes in the Brazilian population. BMC Cardiovasc. Disord. 2008, 8, 40. [CrossRef]
22. Söber, S.; Org, E.; Kepp, K.; Juhanson, P.; Eyheramendy, S.; Gieger, C.; Lichtner, P.; Klopp, N.; Veldere, G.; Viigimaa, M.; et al. Targeting 160 candidate genes for blood pressure regulation with a genome-wide genotyping array. *PLoS ONE* 2009, 4, e6034. [CrossRef] [PubMed]

23. Lei, B.; Morris, D.P.; Smith, M.P.; Svetkey, L.P.; Newman, M.F.; Rotter, J.I.; Buchanan, T.A.; Beckstrom-Sternberg, S.M.; Green, E.D.; Schwinn, D.A. Novel human alpaha1-adrenoceptor single nucleotide polymorphisms alter receptor pharmacology and biological function. *Naunyn Schmiedeberg's Arch Pharmacol.* 2005, 371, 229–239. [CrossRef]

24. Buitenwerf, E.; Boekel, M.F.; van der Velde, M.I.; Voogd, M.F.; Kerstens, M.N.; Wietasch, G.J.K.G.; Scheeren, T.W.L. The hemodynamic instability score: Development and internal validation of a new rating method of intra-operative haemodynamic instability. *Eur. J. Anaesthesiol.* 2019, 36, 290–296. [CrossRef] [PubMed]

25. Gabriel, S.B.; Schaffner, S.F.; Nguyen, H.; Moore, J.M.; Roy, J.; Blumenstiel, B.; Higgins, J.; DeFelice, M.; Lochner, A.; Faggart, M.; et al. The structure of haplotype blocks in the human genome. *Science* 2002, 296, 2225–2229. [CrossRef] [PubMed]

26. Barrett, J.C.; Fry, B.; Maller, J.; Daly, M.J. Haploview: Analysis and visualization of LD and haplotype maps. *Bioinformatics* 2005, 21, 263–265. [CrossRef]

27. Sinnwell, J.P.; Schaid, D.J. *Haplo.Stats: Statistical Analysis of Haplotypes with Traits and Covariates when Linkage Phase is Ambiguous*, R Package Version 1.8.6; R Foundation for Statistical Computing: Vienna, Austria, 2020. Available online: https://CRAN.R-project.org/package=haplo.stats (accessed on 3 March 2021).

28. R Core Team. *R: A Language and Environment for Statistical Computing*; R Foundation for Statistical Computing: Vienna, Austria, 2017; Available online: https://www.R-project.org (accessed on 3 March 2021).

29. Rosskopf, D.; Michel, M.C. Pharmacogenomics of G protein-coupled receptor ligands in cardiovascular medicine. *Pharmacol. Rev.* 2008, 60, 513–535. [CrossRef]

30. Kurnik, D.; Muszkat, M.; Li, C.; Sofowora, G.G.; Friedman, E.A.; Scheinin, M.; Wood, A.J.; Stein, C.M. Genetic variations in the α(2A)-adrenoreceptor are associated with blood pressure response to the agonist dexametomidine. *Circ. Cardiovasc. Genet.* 2011, 4, 179–187. [CrossRef]

31. Büscher, R.; Herrmann, V.; Ring, K.M.; Kailasam, M.T.; O’Connor, D.T.; Parmer, R.J.; Insel, P.A. Variability in phenylephrine response and essential hypertension: A search for human alpha(1B)-adrenergic receptor polymorphisms. *J. Pharmacol. Exp. Ther.* 1999, 291, 793–798.

32. Morrow, A.L.; Creese, I. Characterization of alpha 1-adrenergic receptor subtypes in rat brain: A reevaluation of [3H]WB4104 and [3H]prazosin binding. *Mol. Pharmacol.* 1986, 29, 321–330.

33. Adefurin, A.; Ghimire, L.V.; Kohli, U.; Muszkat, M.; Sofowora, G.G.; Li, C.; Levinson, R.T.; Paranjape, S.Y.; Stein, C.M.; Kurnik, D. Genetic variation in the alpha2A-adrenoceptor gene diversify receptor expression. *Mol. Pharmacol.* 2001, 56, 154–161. [CrossRef] [PubMed]

34. Small, K.M.; Brown, K.M.; Seman, C.A.; Theiss, C.T.; Liggett, S.B. Complete haplotypes derived from noncoding polymorphisms of the intronless alpha2A-adrenergic gene diversify receptor expression. *Proc. Natl. Acad. Sci. USA* 2006, 103, 5472–5477. [CrossRef] [PubMed]

35. McCarthy, M.I.; Abecasis, G.R.; Cardon, L.R.; Goldstein, D.B.; Little, J.; Ioannidis, J.P.; Hirschhorn, J.N. Genome-wide association studies for complex traits: Consensus, uncertainty and challenges. *Nat. Rev. Genet.* 2008, 9, 356–369. [CrossRef] [PubMed]

36. Burton, P.; Clayton, D.; Cardon, L.; Craddock, N.; Duncanson, A.; Kwiatkowski, D.; McCarthy, M.; Ouwehand, W.; Samani, N.; Todd, J.; et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. *Nat. Genet.* 2007, 39, 1329–1337.

37. Herlyn, P.; Müller-Hilke, B.; Wendt, M.; Hecker, M.; Mittlemeier, T.; Gradl, G. Frequencies of polymorphisms in cytokines, neurotransmitters and adrenergic receptors in patients with complex regional pain syndrome type I after distal radial fracture. *Clin J Pain.* 2010, 26, 175–181. [CrossRef]

38. Kelsey, R.M.; Alpert, B.S.; Dahmer, M.K.; Krushkal, J.; Quasney, M.W. Alpha-adrenergic receptor gene polymorphisms and cardiovascular reactivity to stress in Black adolescents and young adults. *Psychophysiology* 2012, 49, 401–412. [CrossRef]

39. Shorter, D.; Nielsen, D.A.; Huang, W.; Harding, M.J.; Hamon, S.C.; Kosten, T.R. Pharmacogenetic randomized trial for cocaine abuse: Disulfiram and alpha1-adrenoceptor gene variation. *Eur. Neuropsychopharmacol.* 2013, 23, 1401–1407. [CrossRef]

40. Wei, W.Q.; Feng, Q.; Weeke, P.; Bush, W.; Waitara, M.S.; Iwuchukwu, O.F.; Roden, D.M.; Wilke, R.A.; Stein, C.M.; Denny, J.C. Creation and Validation of an EMR-based Algorithm for Identifying Major Adverse Cardiac Events while on Statins. *AMIA Jt. Summits Transl. Sci. Proc.* 2014, 112–119. [PubMed]
44. Adefurin, A.; Ghimire, L.V.; Kohli, U.; Muskat, M.; Sofowora, G.G.; Li, C.; Paranjape, S.Y.; Stein, C.M.; Kurnik, D. Genetic variation in the α1A-adrenergic receptor and phenylephrine-mediated venoconstriction. *Pharm. J.* 2015, 310–315. [CrossRef] [PubMed]

45. Shorter, D.; Nielsen, D.A.; Hamon, S.C.; Nielsen, E.M.; Kosten, T.R.; Newton, T.F.; De La Garza, R., 2nd. The α-1 adrenoceptor (ADRA1A) genotype moderates the magnitude of acute cocaine-induced subjective effects in cocaine-dependent individuals. *Pharm. Genom.* 2016, 26, 428–435. [CrossRef] [PubMed]

46. Amorim Belo Nunes, R.; Pereira Barroso, L.; da Costa Pereira, A.; Pinto Brandão Rondon, M.U.; Negrão, C.E.; Krieger, J.E.; Mansur, A.J. Alpha2A-adrenergic receptor and eNOs genetic polymorphisms are associated with exercise muscle vasodilatation in apparently healthy individuals. *Int. J. Cardiol. Heart. Vasc.* 2016, 13, 14–18. [CrossRef]

47. Han, J.; Zuo, J.; Zou, D.; Gao, C. The correlation between SNPs within the gene of adrenergic receptor and neuropeptide Y and risk of cervical vertigo. *J. Clin. Lab. Anal.* 2018, 32, e22366. [CrossRef] [PubMed]

48. Marquez, M.F.; Fragoso, J.M.; Pérez-Pérez, D.; Cázares-Campos, I.; Tomöcch-Serra, A.; Gómez-Flores, J.R.; Vargas-Alarcón, G. Polymorphisms in β-adrenergic receptors are associated with increased risk to have a positive head-up tilt table test in patients with vasovagal syncope. *Rev. Invest. Clin.* 2019, 71, 124–132. [CrossRef]

49. Elia, J.; Capasso, M.; Zaheer, Z.; Lantieri, F.; Ambrosini, P.; Berrettini, W.; Devoto, M.; Hakonarson, H. Candidate gene analysis in an on-going genome-wide association study of attention-deficit hyperactivity disorder: Suggestive association signals in ADRA1A. *Psychiatr. Genet.* 2009, 19, 134–141. [CrossRef]

50. Zhang, X.; Norton, J.; Carriére, I.; Ritchie, K.; Chaudieu, I.; Ryan, J.; Ancelin, M.L. Preliminary evidence for a role of the adrenergic nervous system in generalized anxiety disorder. *Sci. Rep.* 2017, 7, 42676. [CrossRef]

51. Sun, Y.X.; Liao, Y.H.; Zhu, F.; Wang, M.; Chen, X.; Chen, F.; Cao, A.L.; Wang, J. Association between ADRA1A gene polymorphism and autoantibodies against the alpha-1adrenergic receptor in hypertensive patients. *Zhonghua Xin Xue Guan Bing Za Zhi* 2008, 36, 883–887. (In Chinese)

52. Mathias, R.A.; Grant, A.V.; Rafaeles, N.; Hand, T.; Gao, L.; Vergara, C.; Tsai, Y.J.; Yang, M.; Campbell, M.; Foster, C.; et al. A genome-wide association study on African-ancestry populations for asthma. *J. Allergy. Clin. Immunol.* 2010, 126, 336–346.e4. [CrossRef]

53. Hawi, Z.; Matthews, N.; Barry, E. Kirley A, Wagner J, Wallace RH, Heussler HS, Vance A, Gill M, Bellgrove MA; l. A high density linkage disequilibrium mapping in 14 noradrenergic genes: Evidence of association between SLCoA2, ADRA1B and ADHD. *Psychopharmacol.* 2013, 225, 895–902. [CrossRef] [PubMed]

54. Orand, A.; Gupta, A.; Shih, W.; Presson, A.P.; Hammer, C.; Niesler, B.; Heendediya, N.; Mayer, E.A.; Chang, L. Catecholaminergic Gene Polymorphisms Are Associated with GI Symptoms and Morphological Brain Changes in Irritable Bowel Syndrome. *PLoS ONE* 2015, 10, e0139910. [CrossRef] [PubMed]

55. Parkman, H.P.; Mishra, A.; Jacobs, M.; Pathikonda, M.; Sachdeva, P.; Gaughan, J.; Krynetskiy, E. Clinical response and side effects of metoclopramide: Associations with clinical, demographic, and pharmacogenetic parameters. *J. Clin. Gastroenterol.* 2012, 46, 494–503. [CrossRef] [PubMed]

56. Shorter, D.I.; Zhang, X.; Domingo, C.B.; Nielsen, E.M.; Kosten, T.R.; Nielsen, D.A. Doxazosin treatment in cocaine use disorder: Changes in central noradrenergic activity measured by an alpha-1 adrenoreceptor subtype D genetic variant. *Am. J. Drug Alcohol Abuse* 2020, 46, 184–193. [CrossRef]

57. Lima, J.J.; Feng, H.; Duckworth, L.; Wang, J.; Sylvester, J.E.; Kissoon, N.; Garg, H. Association analyses of adrenergic receptor polymorphisms with obesity and metabolic alterations. *Metabolism* 2007, 56, 757–765. [CrossRef]

58. Sickert, L.; Müller, D.J.; Tiwari, A.K.; Shaikh, S.; Zai, C.; De Souza, R.; De Luca, V.; Meltzer, H.H.; Lieberman, J.A.; Kennedy, J.L. Association of the α2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. *Pharmacogenomics* 2009, 10, 1169–1176. [CrossRef]

59. de Cerqueira, C.C.; Polina, E.R.; Contini, V.; Marquez-Perez, F.; Vargas-Alarcón, D.; Ciriaco-Flores, J.R.; Vargas-Abreu, P.; Bau, C.H. ADRA2A polymorphisms and ADHD in adults: Possible mediating effect of personality. *Psychiatry Res.* 2011, 186, 345–350. [CrossRef]

60. Yang, L.; Qian, Q.; Liu, L.; Li, H.; Faraone, S.V.; Wang, Y. Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children. *J. Neural Transm.* 2013, 120, 1127–1133. [CrossRef]

61. Lochman, J.; Balcar, V.J.; Stefányn, F.; Serý, O. Preliminary evidence for association between schizophrenia and polymorphisms in the regulatory Regions of the ADRA2A, DRD3 and SNAP-25 Genes. *Psychiatry Res.* 2013, 205, 7–12. [CrossRef]

62. Rubin, D.H.; Althoff, R.R.; Ehl, E.A.; Davies, G.G.; Rettew, D.C.; Crehan, E.T.; Walkup, J.T.; Hudziak, J.J. Candidate gene associations with withdrawn behavior. *J. Child Psychol Psychiatry* 2013, 54, 1337–1345. [CrossRef]

63. McCracken, J.T.; Badashova, K.K.; Posey, D.J.; Aman, M.G.; Scallill, L.; Tierney, E.; Arnold, L.E.; Vitiello, B.; Whelan, F.; Chuang, S.Z.; et al. Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders. *Pharm. J.* 2014, 14, 295–302. [CrossRef] [PubMed]

64. Cummins, T.D.; Jacoby, O.; Hawi, Z.; Nandam, L.S.; Byrne, M.A.; Kim, B.N.; Wagner, J.; Chambers, C.D.; Bellgrove, M.A. Alpha-2A adrenergic receptor gene variants are associated with increased intra-individual variability in response time. *Mol. Psychiatry* 2014, 19, 1031–1036. [CrossRef]
65. Kochetova, O.V.; Viktorova, T.V.; Mustafina, O.E.; Karpov, A.A.; Khusnutdinova, E.K. Genetic Association of ADRA2A and ADRB3 Genes with Metabolic Syndrome among the Tatars. Genetika 2015, 51, 830–834. [CrossRef] [PubMed]

66. Kaabi, B.; Belaaloui, G.; Benbrahim, W.; Hamizi, K.; Sadelouad, M.; Toumi, W.; Bounecer, H. ADRA2A Germline Gene Polymorphism is Associated to the Severity, but not to the Risk, of Breast Cancer. Pathol. Oncol. Res. 2016, 22, 357–365. [CrossRef] [PubMed]

67. Gómez-Sánchez, C.I.; Riveiro-Alvarez, R.; Soto-Insuga, V.; Rodrigo, M.; Tirado-Reqüero, P.; Mahillo-Fernandez, I.; Abad-Santos, F.; Carbollo, J.J.; Dal-Ré, R.; Ayuso, C. Attention deficit hyperactivity disorder: Genetic association study in a cohort of Spanish children. Behav. Brain Func. 2016, 12, 2. [CrossRef]

68. Hegvik, T.A.; Jacobsen, K.K.; Fredriksen, M.; Zayats, T.; Haavik, J. A candidate gene investigation of methylphenidate response in adult attention-deficit/hyperactivity disorder patients: Results from a naturalistic study. J. Neural Transm. 2016, 123, 859–865. [CrossRef]

69. Adefurin, A.; Darghosian, L.; Okafor, C.; Kawai, V.; Li, C.; Shah, A.; Wei, W.Q.; Kurnik, D.; Stein, C.M. Alpha2A adrenergic receptor genetic variation contributes to hyperglycemia after myocardial infarction. Int. J. Cardiol. 2018, 215, 482–486. [CrossRef]

70. Havranek, M.M.; Hulka, L.M.; Tasudi, E.; Eisenegger, C.; Vomooos, M.; Preller, K.H.; Mössner, R.; Baumgartner, M.R.; Seifritz, E.; Grünblatt, E.; et al. α2A-Adrenergic receptor polymorphisms and mRNA expression levels are associated with delay discounting in cocaine users. Addict. Biol. 2017, 22, 561–569. [PubMed]

71. Myer, N.M.; Boland, J.R.; Faraone, S.V. Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD. Mol. Psychiatry 2018, 23, 1929–1936. [PubMed]

72. Sokol, J.; Skerenova, M.; Ivanjova, J.; Simurda, T.; Stasko, J. Association of Genetic Variability in Selected Genes in Patients With Deep Vein Thrombosis and Platelet Hyperaggregability. Clin. Appl. Thromb. Hemost. 2018, 24, 1027–1032. [CrossRef]

73. Papathanasopoulos, A.; Camilleri, M.; Carlson, P.J.; Vella, A.; Nord, S.J.; Burton, D.D.; Odusni, S.T.; Zinsmeister, A.R. A preliminary candidate genotype-phenotype study of satiation and gastric motor function in obesity. Obesity 2010, 18, 1201–1211. [CrossRef] [PubMed]

74. Cho, S.C.; Kim, J.W.; Kim, H.W.; Kim, B.N.; Shin, M.S.; Cho, D.Y.; Jung, S.W.; Chung, U.S.; Son, J.W. Effect of ADRA2A and BDNF gene-gene interaction on the continuous performance test phenotype. Psychiatr Genet. 2011, 21, 132–135. [CrossRef] [PubMed]

75. Talmud, P.J.; Cooper, J.A.; Gaunt, T.; Holmes, M.V.; Shah, S.; Palmen, J.; Drenos, E.; Shah, T.; Kumari, M.; Kivimaki, M.; et al. Variants of ADRA2A are associated with fasting glucose, blood pressure, body mass index and type 2 diabetes risk: Meta-analysis of four prospective studies. Diabetologia 2011, 54, 1710–1719. [CrossRef] [PubMed]

76. Bo, S.; Cassader, M.; Cavallo-Perin, P.; Durazzo, M.; Rosato, R.; Gambino, R. The rs553668 polymorphism of the ADRA2A gene predicts the worsening of fasting glucose values in a cohort of subjects without diabetes. A population-based study. Diabet. Med. 2012, 29, 549–552. [CrossRef]

77. Li, T.; Zhu, X.; Wu, X.; Li, J.; Pan, L.; Xin, Z.; Gu, H.F.; Liu, Y. Evaluation of the association between the ADRA2A genetic polymorphisms and type 2 diabetes in a Chinese Han population. Genet. Test. Mol. Biomark. 2012, 16, 1424–1427. [CrossRef]

78. Mlakar, V.; Jurkovic Mlakar, S.; Zupan, J.; Komadina, R.; Prezelj, J.; Marc, J. ADRA2A is involved in neuro-endocrine regulation of bone resorption. J. Cell. Mol. Med. 2015, 19, 1520–1529. [CrossRef]

79. Nunes, R.A.; Lima, L.B.; Tanaka, N.I.; da Costa Pereira, A.; Krieger, J.E.; Mansur, A.J. Genetic associations of bradykinin type 2 receptor, alpha-adrenoceptors and endothelial nitric oxide synthase with blood pressure and left ventricular mass in outpatients without overt heart disease. Int. J. Cardiol. Heart Vasc. 2018, 21, 45–49. [CrossRef]

80. Xu, D.; Liu, L.; Li, H.; Sun, L.; Yang, L.; Qian, Q.; Wang, Y. Potential Role of ADRA2A Genetic Variants in the Etiology of ADHD Comorbid With Tic Disorders. J. Atten. Disord. 2021, 25, 33–43. [CrossRef]

81. Leońska-Duniec, A.; Jastrzębski, Z.; Jaźdżewska, A.; Moska, W.; Lulińska-Kuklik, E.; Sawczuk, M.; Gubaydullina, S.I.; Shakirova, A.T.; Cieszczyk, P.; Maszczyk, A.; et al. Individual Responsiveness to Exercise-Induced Fat Loss and Improvement of Metabolic Profile in Young Women Is Associated with Polymorphisms of Adrenergic Receptor Genes. J. Sports Sci. Med. 2018, 17, 134–144. [PubMed]

82. Totomoch-Serra, A.; de Lourdes Muñoz, M.; Burgueño, J.; Revilla-Monsalve, M.C.; Perez-Muñoz, A.; Diaz-Badillo, Á. The ADRA2A rs553668 variant is associated with type 2 diabetes and five variants were associated at nominal significance levels in a population-based case-control study from Mexico City. Gene 2018, 669, 28–34. [CrossRef]

83. Mągurean, C.O.; Mągurean, C.; Bănescu, C.; Melit, L.E.; Tripop, F.; Iancu, M. The relationship between MMP9 and ADRA2A gene polymorphisms and mothers-newborns’ nutritional status: An exploratory path model (STROBE compliant article). Pediatr. Res. 2019, 85, 822–829. [CrossRef] [PubMed]

84. Perroud, N.; Aitchison, K.J.; Uher, R.; Smith, R.; Huez-Diaz, P.; Marusic, A.; Maier, W.; Mors, O.; Placentino, A.; Henigsberg, N.; et al. Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacol. 2009, 34, 2517–2528. [CrossRef] [PubMed]

85. Song, Y.; Tang, X.F.; Yao, Y.; He, C.; Xu, J.J.; Wang, H.H.; Gao, Z.; Wang, M.; Yuan, J.Q. Association of α2A-Adrenergic Receptor Genetic Variants with Platelet Reactivity in Chinese Patients on Dual Antiplatelet Therapy Undergoing Percutaneous Coronary Intervention. Biomed. Environ. Sci. 2017, 30, 898–906. [PubMed]

86. Clarke, T.K.; Dempster, E.; Docherty, S.J.; Desrivieres S, Lourdsamy A, Wodarz N, Ridering M, Maier W, Rietshel M, Schumann G. Multiple polymorphisms in genes of the adrenergic stress system confer vulnerability to alcohol abuse. Addict. Biol. 2012, 17, 202–208. [CrossRef] [PubMed]
87. Hiltunen, T.P.; Donner, K.M.; Sarin, A.P.; Saarela, J.; Ripatti, S.; Chapman, A.B.; Gums, J.G.; Gong, Y.; Cooper-DeHoff, R.M.; Frau, F.; et al. Pharmacogenomics of hypertension: A genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs. *J. Am. Heart Assoc.* **2015**, *4*, e001521. [CrossRef] [PubMed]

88. Muszkat, M.; Kurnik, D.; Sofowora, G.G.; Solus, J.; Xie, H.G.; Harris, P.A.; Williams, S.M.; Wood, A.J.; Stein, C.M. Desensitization of vascular response in vivo: Contribution of genetic variation in the [alpha]2B-adrenergic receptor subtype. *J. Hypertens.* **2010**, *28*, 278–284. [CrossRef]

89. De Fusco, M.; Vago, R.; Striano, P.; Di Bonaventura, C.; Zara, F.; Mei, D.; Kim, M.S.; Muallem, S.; Chen, Y.; Wang, Q.; et al. The α2B-adrenergic receptor is mutant in cortical myoclonus and epilepsy. *Ann. Neurol.* **2014**, *75*, 77–87. [CrossRef]